We've updated our Privacy Policy to make it clearer how we use your personal data.

We use cookies to provide you with a better experience, read our Cookie Policy

MorphoSys Initiates Phase 2 Study of MOR208 in NHL

News   May 13, 2013

 
MorphoSys Initiates Phase 2 Study of MOR208 in NHL
 
 
 

RELATED ARTICLES

Anti-inflammatory Drug May Raise Diabetes Risk

News

A commonly prescribed anti-inflammatory drug may increase diabetes risk after just one week of treatment, according to new findings presented at The Society for Endocrinology Annual Conference.

READ MORE

Progress on Vaccines Against Four Types of Hemorrhagic Fever Viruses

News

Scientists have developed a new vaccine that protected monkeys against four types of hemorrhagic fever viruses endemic to regions in Africa.

READ MORE

GW Pharmaceuticals Receives Positive NICE Recommendation for EPIDYOLEX (Cannabidiol)

News

GW Pharmaceuticals plc announces that two of its medicines, EPIDYOLEX (cannabidiol) oral solution and Sativex (nabiximols), have been recommended by the UK’s National Institute for Health and Care Excellence (NICE) to receive routine reimbursement from NHS England.

READ MORE

 

Like what you just read? You can find similar content on the communities below.

Immunology & Microbiology

To personalize the content you see on Technology Networks homepage, Log In or Subscribe for Free

LOGIN SUBSCRIBE FOR FREE